. Their discovery is facilitated by technologies that allow genome-wide measurement of DNAm in a high-throughput manner 11 . Importantly, the metastability of DNAm and the DNA-based nature of the assays provide important technical advantages over measuring histone modifications or mRNA expression. In particular, DNAm assays based on bisulfite conversion are highly quantitative and reproducible, offering high sensitivity to detect small (~1%) changes in DNAm from samples with limited amounts of available DNA. Among these, the Illumina BeadChip microarray technology 12, 13 offers a good compromise between cost and coverage and is so far the most popular choice for epigenome-wide association studies (EWAS), which require DNAm measurements in hundreds if not thousands of samples 13 . By contrast, the higher coverage and cost of whole-genome bisulfite sequencing (WGBS) and reduced-representation bisulfite sequencing (RRBS) make these the optimal technologies for mapping reference DNA methylomes, as generated by international consortia such as the US National Institutes of Health (NIH) Roadmap Epigenomics Project, the International Human Epigenome Consortium (IHEC) and BLUEPRINT 14, 15 , or for measuring genome-wide DNAm patterns from low-yield DNA samples such as cell-free DNA (cfDNA) in plasma 16 . Rigorous and reliable inference from DNAm data is key to a wide range of downstream tasks in EWAS, including the identification of disease biomarkers and causal relationships. These tasks require careful statistical analyses, starting with quality control steps that assess the reliability of the data, followed by intra-sample normalization to adjust for sample-specific technical biases (for example, incomplete bisulfite conversion and background correction). Beyond the obvious importance and need for such normalization, downstream statistical analyses need to deal with other challenges, notably including batch effects and other confounding factors, feature selection and integration with other types of omic data. Given that DNAm is highly cell-type-specific, cell-type heterogeneity of complex tissues (for example, blood or breast) constitutes a major confounder, requiring the application of cell-type deconvolution algorithms. These algorithms offer a form of in silico or virtual microdissection, allowing inference of DNAm changes that are not driven by alterations in tissue composition. Other DNAm alterations have been found to be reproducibly associated with different environ mental factors (for example, smoking and obesity)
Intra-sample normalization
The procedure of adjusting the raw data profile of a biological sample for technical biases and artefacts. This is often followed by inter-sample normalization, in which adjustments are made to the data for technical and biological factors that otherwise cause unwanted (and often confounding) data variation across samples.
Confounding
When the relationship between an exposure and an outcome is not causal but is due to the effects of a third variable (the confounder) on the exposure and the outcome. White blood cell heterogeneity can act as a confounder in many epigenetic studies.
Feature selection
The statistical procedure of identifying features which, in some broad sense, correlate with an exposure or phenotype of interest (POI).
Differentially methylated cytosines
(DMCs). Cytosines (usually in a CpG context) that exhibit a statistically significant difference in DNA methylation between two groups of samples, according to some statistical test.
Condition number
In the context of reference-based cell-type deconvolution, the condition number of a reference matrix represents an index of the numerical stability of the inference. Formally, it measures the sensitivity of the regression parameters (also known as cell weights) to small perturbations or errors in the reference matrix.
by DNAm being an imperfect measure of gene activity, thus requiring integration with other types of data (for example, mRNA expression or chromatin immunoprecipitation followed by sequencing (ChIP-seq)) in order to help improve causal inference and interpretation. Although statistical methods for such integrative ana lyses are underdeveloped, the technical reliability of DNAm measurements makes DNAm the ideal epigenetic focal point for such system-level analyses.
Here, we discuss the aforementioned statistical challenges and review the corresponding computational algorithms and software, focusing throughout on downstream analyses, that is, after intra-sample normalization. We first consider confounding factors, owing to the need to determine the major sources of inter-sample variation, with an emphasis on cellular heterogeneity and cell-type deconvolution algorithms. Next, we turn to the main task of an EWAS, which is feature selection. To help with the interpretation of EWAS data, we subsequently describe methods for integrating DNAm with other types of omic data, such as genotype, mRNA expression and transcription factor (TF) binding data, including approaches to strengthen causal inference. We end with an outlook on outstanding statistical challenges and a prediction of how the field will develop. Details of technologies for generating DNAm data and associated intra-sample normalization methods are not covered here, as they were recently reviewed elsewhere [21] [22] [23] [24] .
Cell-type heterogeneity and deconvolution EWAS seek to identify differentially methylated cytosines (DMCs) between cases and controls. This task is hampered by variations in the proportions of cell types that make up the tissue where DNAm is measured. These proportions may vary substantially between cases and controls, and while this variation may be biologically and clinically important 25, 26 , they often reflect changes that are consequential of the disease state, hampering the identification of alterations that may drive disease risk or progression [27] [28] [29] . For example, rheumatoid arthritis (RA) was shown to be associated with a shift in the granulocyte-to-lymphocyte ratio, leading to thousands of DMCs, most of which disappeared upon correction for cell-type composition 30 . In general, cell-type deconvolution methods are needed to address any of the following four aims: estimation of absolute or relative cell-type fractions within the samples of interest; identification of DMCs that are not the result of changes in cell-type composition; identification of DNAm profiles representing cell types in the tissue of interest; and identification of the cell type (or types) carrying the DMCs. Broadly speaking, statistical paradigms for cell-type deconvolution fall into two main categories, called 'reference-based' (REF. 31) (if it uses a priori defined DNAm reference profiles of represen tative cell types in the tissue of interest) and 'reference-free' (REF. 32) 
. Other work has developed a third paradigm ('semi-reference-free ') 33,34 , which circumvents some of the disadvantages of both reference-free and reference-based methods
.
Reference-based cell-type deconvolution. The main requirements underlying reference-based inference are that the main constituent cell types of the tissue are known and that reference molecular profiles representing these cell types are available. Importantly, the reference profiles need to be defined only over features that are informative of differences between cell types; for example, in the DNAm context, they should ideally represent cell-type-specific DNAm markers or be highly discriminative of the different cell subtypes in the tissue of interest. The construction of such reference profiles usually needs to be completed in advance of the study, and it typically requires the generation of genome-wide DNAm data of cell populations purified by fluorescenceactivated cell sorting (FACS) or magnetic-activated cell sorting (MACS), followed by statistical analysis to select DMCs between cell subtypes. The importance of constructing a high-quality reference profile database has recently been highlighted 35 . For instance, similar cell types are likely to have highly collinear profiles, which may result in unstable parameter estimation 36 . This is of particular concern if quality control causes a relatively large number of CpGs present in the reference database to drop out, which may further aggravate the collin earity. Hence, it has been proposed that a reference database should maximize the condition number of the matrix it defines 37 , which in effect ensures maximal stability of the inference to random loss of features in the reference database.
Assuming a reference database exists, there are then two approaches to infer cell-type fractions within a sample of interest. Both methods effectively run a multivariate regression of the DNAm profile of the sample against the reference DNAm profiles as covariates, with the estimated regression coefficients corresponding to cell-type fractions (if appropriately normalized) (FIG. 1Aa) . A widely known technique named constrained projection (CP) (also called quadratic programming (QP)) performs least-squares multivariate regression while imposing normalization constraints on the regression coefficients, which allows the estimated co efficients to be directly interpreted as cell-type proportions within the sample 31, 38 . An alternative 'non-constrained' approach is to impose the non-negativity and normalization constraints after estimation of the regression coefficients. This is the approach taken by CIBERSORT, which implements a penalized multivariate regression, originally presented in the context of gene expression data 37 . A similar non-constrained approach can be taken with robust partial correlation (RPC) (a robust form of multivariate regression) 37, 39 . A recent comparative DNAm study of CP, CIBERSORT and RPC concluded that for realistic noise levels, RPC and CIBERSORT might be preferable over CP 39 , consistent with findings obtained for gene expression data 37 . Methods such as CP or CIBERSORT use reference DNAm profiles defined as the average DNAm over biological replicates, using DMCs that maximize the differences in mean methylation between cell types. Ideally, these DMCs would also exhibit very stable (that is, ultra-low variance) DNAm profiles within cell types, appearing as strongly bi-modal profiles. However, depending on the tissue and cell types, such bi-modal DMCs may not be present, so it may also be necessary to include the variance in DNAm when performing reference-based deconvolution. For instance, an algorithm called CancerLocator models reference DNAm profiles using beta distributions, generating betadistribution references for healthy plasma DNA and solid tumours, subsequently using a two-state betamixture model to infer tumour burden and tissue of origin of circulating tumour DNA (ctDNA) in plasma 40 ( FIG. 1Ab) . Similarly, algorithms for inferring tumour purity of primary cancers also use explicit beta distributions and have been shown to provide accurate estimates, in line with gold-standard estimates derived from copy-number data [41] [42] [43] .
Reference-free cell-type deconvolution. To date, there are two main types of reference-free methods
, which differ greatly in terms of their model assumptions. One class is widely known as surrogate variable analysis (SVA) [44] [45] [46] , an approach developed originally to address general unknown confounding factors and that has also gained considerable favour for cell-type deconvolution [47] [48] [49] . SVA uses the phenotype of interest (POI) from the outset and attempts to construct 'surro gate variables' that capture confounding variation of any sort (that is, not just cell-type compositional changes but, for example, also batch effects) in the space of variation that is 'orthogonal' to that associated with the POI 44, 45, 50 . A variant of SVA, called RefFreeEWAS 32 , assumes an explicit mixture-modelling structure (as required for modelling cell-type composition) and has been demonstrated to work well 32, 51 . Another variant of SVA, called independent surrogate variable analysis (ISVA) 50 , is similar to SVA but uses a blind source separation (BSS) algorithm (independent component analysis (ICA) 52 ) instead of principal component analysis (PCA) in the residual variation space, which may help to identify a more relevant subspace of confounding variation (that is, a subset of surrogate variables). The need for this subspace selection step may arise if the model describing the effect of the POI on the data is a poor one, as this may result in variation associated with the POI being found in the surrogate variable subspace 50 . Unlike PCA, BSS is designed to disentangle independent sources of variation 52 and is therefore better suited for deconvolving the residual biological variation associated with the POI from potential confounding variation.
Another set of reference-free approaches, exemplified by methods such as EWASher 53 or ReFACTor 54 , do not use the phenotype of interest when inferring latent components associated with cell-type composition. This is only possible if certain assumptions are made. Specifically, EWASher and ReFACTor assume that the top principal component of variation in the data is associated with changes in cell-type composition, an assumption that will not hold if the POI accounts for a larger proportion of data variance. Thus, the applicability of these two methods is critically dependent on the POI and the underlying tissue type (FIG. 1B) .
Box 1 | Statistical inference paradigms for cell-type deconvolution
Reference-based cell-type deconvolution tools These methods correct for cell-type heterogeneity by using an existing reference DNA methylation (DNAm) database of cell types that are thought to be present in the tissue of interest. If the main underlying cell types of the tissue are known, then estimates of the absolute cell-type fractions are possible; otherwise, estimated fractions are relative. The estimated absolute or relative cell-type fractions can then be used as covariates in supervised multivariate regression models to infer differentially methylated cytosines (DMCs) that are independent of changes in cell-type composition.
Advantages
• Absolute or relative cell-type fractions can be estimated in each individual sample.
• If required, they can be easily combined with batch-correction methods such as COMBAT.
• The model itself is relatively assumption free.
Disadvantages
• The tools require knowledge of the main cell types that are present in the tissue.
Reliable reference DNAm profiles must be available for these cell types.
• On their own, they cannot deal with unknown confounding factors.
• They assume that cell-cell interactions in the sample do not affect the DNAm profiles of the individual cell types.
• Reference profiles could be confounded by factors such as age or genotype.
Reference-free cell-type deconvolution tools
These methods correct for cell-type heterogeneity by inferring from the full data matrix 'surrogate variables', which include sources of data variation that are driven by cell-type composition. These surrogate variables are inferred from the data without the need for a reference DNAm database and are used as covariates in the final supervised multivariate regression model to infer DMCs that are independent of changes in cell-type composition and other cofounders.
Advantages
• There is no requirement to know the main cell types in a tissue or to have reference DNAm profiles; hence, in principle, they are applicable to any tissue type.
• De novo (unsupervised) discovery of novel cell subtypes.
• They allow for the possibility that cell-cell interactions alter the profiles of individual cell types.
• They can adjust simultaneously for other confounding factors, known or unknown.
Disadvantages
• Without further biological input, they cannot provide estimates of cell-type fractions in individual samples.
• Performance is strongly dependent on model assumptions, which are often not satisfied.
Semi-reference-free cell-type deconvolution tools
This is a third paradigm that corrects for cell-type heterogeneity by inferring surrogate variables representing variation due to cell-type composition but that, unlike a purely 'reference-free' approach, does so by using partial prior biological knowledge of which cytosine-guanine dinucleotides (CpGs) differ between cell types. Typically, these tools infer the surrogate variables from the reduced data matrix, projected on this set of selected features.
Advantages
• They allow for the possibility that cell-cell interactions alter the DNAm profiles of individual cell types.
• If required, they can be combined with batch-correction methods such as COMBAT.
• They are more robust to incomplete knowledge of underlying cell types in the tissue of interest.
• They can provide approximate relative estimates of cell-type fractions in individual samples.
Disadvantages
• Performance is still strongly dependent on model assumptions, which may not be satisfied.
• Inference of absolute cell-type fractions in individual samples remains challenging.
• The ability to resolve highly similar cell types is limited. Aa | Estimating cell-type fractions in a sample for which a genome-wide DNA methylation (DNAm) profile is available is an important task, as changes in these proportions can have biological and clinical importance or can confound analyses. Constrained projection (CP) infers these proportions by running a constrained multivariate regression model of the sample' s DNAm profile against reference DNAm profiles for the cell types of interest, with the estimated regression coefficients (w 1 , w 2 and w 3 ) representing cell proportions. Ab | From a plasma sample, estimating the relative fractions of cell-free DNA (cfDNA) from healthy cells versus circulating tumour DNA (ctDNA) presents a novel promising clinical application for non-invasive early detection and disease monitoring. The CancerLocator algorithm (TABLE 1) allows estimation of the tumour burden (denoted f) and the type of tumour. B | Cell-type heterogeneity may cause confounding and compromise the identification of differentially methylated cytosines (DMCs) in epigenome-wide association studies (EWAS). The diagram presents recommendations as to which statistical algorithms might be better suited for different EWAS scenarios. This depends on whether reference DNAm profiles are available, the presence of unknown confounders and technical batch effects (known confounders). When reference profiles are available, reference-based methods are recommended unless there is evidence of other confounding variation, in which case surrogate variable analysis (SVA)-like methods are preferable. If partial prior information is available, such as if cell-type-specific DMCs (tDMCs) are known but no reference profiles are available, a semi-reference-free approach like RefFreeCellMix is recommended. Relative data variation between the phenotype of interest (POI) and that due to cell-type heterogeneity is important when deciding between reference-free methods. Finally, DMCs are inferred using a multivariate regression of the data against the POI (F denotes the link function) and cell-type fractions or surrogate variables as covariates (denoted Q). Note that regression coefficients have been omitted for the sake of clarity. C | A third important task is the quantification of epigenetic heterogeneity within a given cell type, for instance, quantifying clonal heterogeneity within tumour cells. Given that DNAm normally exhibits strong spatial correlations on scales up to approximately 500 bp and that tumours are characterized by widespread deviations from the DNAm ground state, one way to approximate clonal epigenetic heterogeneity is to measure the proportion of discordant reads (PDR). Tumours characterized by high epigenetic clonal heterogeneity have been found to exhibit worse clinical outcome (see the main text). For specific algorithms mentioned in this figure, see 
Beta distributions
The distributions of beta values. The beta value is a statistical term used to describe the quantification of DNA methylation at a given cytosine, as the ratio of methylated alleles to the total number of alleles (methylated + unmethylated), a number that by definition must lie between 0 (fully unmethylated) and 1 (fully methylated).
Surrogate variable analysis
(SVA). A widely used technique for selecting features associated with a factor of interest, which is not confounded by other factors. SVA uses a model to identify the data variation that is orthogonal to the factor of interest and subsequently uses principal component analysis (PCA) on this orthogonal variation matrix to construct 'surrogate variables', which in theory should capture confounding sources of variation.
Phenotype of interest
(POI). The factor or variable of interest in an epigenome-wide association study (EWAS). This factor is often binary, representing case-control status, but could also represent an ordinal variable (for example, genotype) or be continuous (for example, age).
Blind source separation
(BSS). The problem of inferring the sources of variation gives rise to a data matrix without using any prior information ('blind'). Algorithms that can achieve this are called BSS algorithms, of which independent component analysis (ICA) is one example.
For instance, the assumption underlying EWASher and ReFACTor may hold in whole blood for a wide range of phenotypes because the granulocyte fraction varies substantially, even among healthy individuals (see, for example, REF. 39 ), yet in a less complex tissue such as peripheral blood, which is devoid of granulocytes, celltype compositional changes could account for a much smaller proportion of total data variance. Similarly, in diseases such as cancer, which are characterized by large-scale changes in DNAm, involving most of the genome, only a smaller fraction of these changes are due to changes in cell-type composition 48, 55 . Thus, methods such as ReFACTor or EWASher may not offer the level of sensitivity required for many types of EWAS 48 .
Semi-reference-free cell-type deconvolution. A promising third paradigm, which remains underexplored, can be viewed as semi-reference-free
. Conceptually, it adapts the removing unwanted variation (RUV) framework 56 , in that it attempts to infer 'empirical control features' , that is, features affected by confounding variation but not associated with the POI, which can subsequently be used to adjust the data. In the context of cell-type deconvolution, a pre-specified set of cell-typespecific DMCs (for example, DMCs that differ between blood cell subtypes) could serve as empirical control features 34, 57 . A recent algorithm, called RefFreeCellMix, which uses a constrained form of non-negative matrix factorization (NMF), can be easily adapted in this semi-reference-free manner to infer cell-type proportions 33 . By performing NMF on the reduced data matrix obtained by selecting cell-type-specific DMCs, RefFreeCellMix can obtain estimates of cell-type fractions, from which DMCs associated with a POI can subsequently be inferred using supervised regression. This approach was recently applied to the deconvolution of breast cancer samples (EDec algorithm) 34 . More recently, a regularized version of RefFreeCellMix, called MeDeCom 58 , which favours latent factors (representing cell-type-specific DNAm profiles) that exhibit bi-modal (that is, fully unmethylated or methylated) methylation states, has been shown to lead to improved modelling of cell-type composition. All these algorithms also offer a means of identifying the specific cell types carrying the DNAm alterations, although this remains largely unexplored.
Comparison of cell-type deconvolution algorithms. For a given EWAS, the choice of cell-type de convolution algorithm depends mainly on the availability of a suitable reference DNAm database. The database could be confounded by external factors such as age or genotype, rendering the references less useful for application to data sets where these factors might be very different (for example, using adult blood cell subtype reference profiles to estimate cell subtype fractions in umbilical cord blood 59 ); in other cases, reference profiles generated on purified cell populations may not capture important in vivo cell-cell interactions, which are known to alter molecular profiles 60 
. Beyond these limitations, there are three additional factors to consider when choosing a cell-type deconvolution method: first, the specific information desired (for example, DMCs, cell-type fractions or unsupervised discovery of novel cell types); second, the presence of additional confounding factors and whether these are known or unknown; and third, the POI and tissue type, which determines the relative data variance associated with the POI and cell-type composition. Recommendations and guidelines for different scenarios are provided (see FIG. 1B) and are largely in agreement with those of recent comparative studies [47] [48] [49] 61 . Briefly, for DMC detection in tissues for which the main underlying cell types are known, reference-based methods, which are relatively assumption free and which can be combined with batch-correction methods such as COMBAT 62 , are recom mended, unless confounders are unknown, in which case a method like SVA is preferable. Referencefree or semi-reference-free methods are necessary for tissues for which no reference DNAm profiles are available. Because reference-free methods are more dependent on model assumptions, special care must be taken in selecting the most appropriate method, which will depend by and large on the relative data variance carried by the POI and cell-type composition, as well as on the presence of unknown confounders (FIG. 1B) . For estimating cell-type fractions, a reference-based algorithm is most appropriate, although semi-reference-based algorithms such as RefFreeCellMix or MeDeCom could also be used if the inferred latent components are uniquely mappable to underlying cell types 33 . Finally, one may also wish to perform cell-type deconvolution in order to discover novel cell types in a tissue of interest. This un supervised application would require application of methods such as RefFreeCellMix or MeDeCom on the full set of available CpGs rather than on an informed subset of cell-type-specific DMCs.
Epigenetic heterogeneity within cell types. Epigenetic heterogeneity also manifests itself within specific cell types 63 , notably pluripotent cells 64 and cells of the immune system 65 , but also within haemato logical cancers 66, 67 and the epithelial compartments of solid tumours 55, 68 . In the context of precursor cancer lesions, such epigenetic heterogeneity is believed to be an important driver of cancer risk, whereas in cancer, clonal heterogeneity determines disease progression and response to drug treatment 66 . Thus, there is substantial interest in developing statistical measures that can quantify epigenetic clonal heterogeneity. Such quantification is best done using WGBS or RRBS data, because associated reads (representing strings of binary methylated or unmethylated calls at single-nucleotide resolution) have the required spatial resolution to allow epiallelic diversity to be estimated (FIG. 1C) . Also of particular importance is the detection of shifts in the proportions of specific epialleles, for which algorithms (for example, methclone 69 ) have been developed. In the context of Illumina methylation bead arrays, identifying epigenetic loci marking shifts in epigenetic subclones is possible using statistical tests for detecting methylation outliers 55 . 
Principal component analysis
(PCA). An unsupervised dimensionality reduction algorithm that decomposes the data matrix into a sum of linear principal components (PCs) of variation, ranked by decreased variance and uncorrelated to each other.
Latent components
Components or sources of data variation that are 'hidden' (or latent) and that are inferred from the data using an unsupervised algorithm.
Feature selection and interpretation
The most common task in analysing omic data is feature selection. For any given EWAS, it is useful to think of CpG DNAm profiles as belonging to specific 'families' , each characterized by a particular pattern or shape and each linked to an underlying putative biological (or technical) factor. For instance, DNAm variation of CpGs marking specific cell types will typically exhibit patterns of DNAm variation that correlate linearly with the underlying cell-type fractions, whereas those driven by genetic variants will not. Given that current technologies allow measurement of DNAm in effectively one million to several million CpG sites, small differences in feature selection methods can have a dramatic impact on the specific ranking and selection of CpGs. An appreciation of the intricacies of feature selection is therefore critically important.
Variably methylated cytosines. A popular un supervised feature selection strategy is to rank and filter features by variance or by a robust version such as the median absolute deviation; the aim is to select the most variably methylated cytosines (VMCs), while also removing those that exhibit little or no variance (which are assumed to represent noise) 70 . However, applying this strategy to DNAm data could bias the selection of features, given that DNAm data are usually quantified in terms of a beta value, which by construction is heteroscedastic. In fact, for beta values, variance is maximal at a value of 0.5 (REF. 71); hence, filtering by variance could favour genomic regions with intermediate mean levels of DNAm. Filtering tools that avoid this bias have been developed 72 . Alternatively, DNAm may be quantified in terms of M-values 71 , which can be obtained directly from the log-ratio of intensities of methylated to un methylated alleles or indirectly from beta values by applying the logit transformation. In principle, M-values are more homoscedastic, although care must be taken with features that have methylation beta values close to 0 or 1, as the logit transformation can turn these into significant outliers 71, 73 . In general, VMCs will exhibit a large range of DNAm values and will include those driven by singlenucleotide polymorphisms (SNPs). For a substantial number of these VMCs, the variation will be driven by a SNP affecting the interrogated cytosine (or another cytosine located within the probe body in the case of Illumina bead arrays), and such VMCs are normally removed during quality control 74, 75 . For other VMCs, the SNP driving the variation will not be located at the interrogated cytosine (nor in the underlying probe), thus defining methylation quantitative trait loci (mQTLs) 76 (FIG. 2a) . Although mQTLs are highly variable, they are not always prominent features driving top components in a PCA unless the study cohort consists of populations stratified by ancestry 18, 76, 77 . This is because principal components represent components of maximal covariation, so that mQTLs (especially those with low minor allele frequencies) account for only relatively smaller fractions of data covariance.
Other VMCs that will appear more prominently in top principal components may be associated with other biological factors such as cell-type composition (FIG. 2a) or may exhibit strongly bi-modal profiles such as those seen in cancer.
Differentially methylated cytosines and regions. The most common supervised feature selection procedure is to select CpGs for which there is a significant difference in the average between phenotypes, defining DMCs (FIG. 2b) . The simplest method for selecting DMCs is that based on the absolute difference in mean beta values, which is analogous to the log-fold-change 68 . For the mQTL, samples are grouped according to the predicted genotype. For the other VMC, blue denotes normal cervical smears from women who 3 years after sample collection developed a cervical intraepithelial neoplasia of grade two or higher (CIN2+), whereas green denotes normal cervical smears from women who remained healthy. This particular VMC is unmethylated in all white blood cells (WBC) but not in cervical epithelial cells, and so the variation in the cervical smear is due to variation in WBC contamination. Panels illustrate how SNPs and cell-type composition can drive large variation in DNAm, but variation that may not correlate with case versus control status. b | Contrast between differentially methylated cytosines (DMCs) and differentially variable cytosines (DVCs). Two examples of each are given, drawn from Illumina Infinium DNAm data from normal cervical smears (green) and either cervical intraepithelial neoplasia (CIN2+) or cervical cancer (both blue). The average levels are shown as horizontal dashed lines. Observe how a DMC is typically characterized by most samples in one phenotype exhibiting a deviation in DNAm value. By contrast, a DVC is characterized by a very stable DNAm profile in one phenotype but by DNAm outliers driving large variation in the other. c | Example of a CpG that exhibits progression in DNAm between successive stages in cervical carcinogenesis. When comparing normal cervical smears that progress to CIN2+ (Normal→CIN2+) to those that do not (Normal→Normal), this CpG can be identified (that is, with a highly significant P-value) only via a test for differential variance (or for deviation from normality) such as Bartlett's test. When comparing CIN2+ to normal cervical smears, differential variance is still the main distinguishing feature. Only when comparing (invasive) cervical cancer to normal cervix does this CpG exhibit a stronger difference in average DNAm, therefore enabling its identification using, for example, t-tests or Wilcoxon tests. Thus, this panel illustrates how the DNAm profile of the same CpG changes during cervical carcinogenesis and emphasizes the importance of selecting the appropriate statistical test, as the choice of test will have a dramatic impact on feature selection. All data shown represent real DNAm data derived from REF. 68 , with the corresponding CpG identifier given above each panel.
Variably methylated cytosines
(VMCs). Cytosines (usually in a CpG context) that exhibit a significant amount of variance in DNA methylation, as assessed across independent samples and relative to other CpG sites.
Heteroscedastic
Of a statistical distribution or of a random sample thereof, the expected variance, or spread, being dependent on the mean. 
Logit transformation

Differentially variable cytosines
(DVCs). Cytosines (usually in a CpG context) that exhibit a statistically significant difference in the variance of DNA methylation between two groups of samples, according to some statistical test.
Field defects
Genetic or epigenetic alterations that are thought to predate the development of cancer and that are usually seen in the normal tissue found adjacent to cancer.
used in the gene expression context. However, because of the heteroscedasticity of beta values, such filtering may again bias selection against CpGs with very low or very high mean levels of methylation 71 . A much safer option is to apply such thresholding on differences in mean beta value only after having ranked or selected features based on some formal statistic, as the statistic incorporates information about the spread of the data within phenotypes. One option is to use non-parametric Wilcoxon rank sum tests, as these consider only the relative ranking of beta values, although a caveat is that these tests are less powered. Another option is to use t-tests. Although t-tests require the data within the phenotypes being compared to be Gaussian distributed (an assumption not satisfied with beta-valued data), nevertheless, in practice, this does not impose any more of a limitation than the non-Gaussian nature of, for example, gene expression data from microarrays or RNA sequencing (RNA-seq), for which empirical Bayesian frameworks built on regularized t-statistics have proved extremely popular [78] [79] [80] . For feature selection, what matters is the distribution of values across samples, and for both DNAm and mRNA expression data, this distribution is approximately Gaussian. Confirming this, t-statistics and moderated t-statistics have been successfully applied to beta-valued data and shown to lead to very similar rankings compared to the application of the same statistics to M-values 73 . An important exception is when using Bayesian models, which are naturally more sensitive to underlying model assumptions (often Gaussian distributions). For instance, in studies with small sample sizes, empirical Bayes models are necessary for obtaining improved estimates of variance, thus favouring M-values 71, 73 . DMCs derived from t-tests or regularized t-tests may or may not exhibit large differences in average DNAm, since a CpG exhibiting a small (for example, 5%) difference in mean methylation but with low variance within phenotypes may still have a large t-statistic. Many smoking-associated DMCs identified in whole blood are of this type 17 . Cancer DMCs, on the other hand, generally exhibit much larger differences in mean DNAm (>30% , FIG. 2b) .
Differential methylation can also be called at the regional level. There are a number of reasons why identifying differentially methylated regions (DMRs) is desirable. First, due to the processivity of DNA methyltransferases and other enzymes modifying the epigenome, DNAm is generally highly correlated on scales up to approximately 500 bp and beyond 16, 81 . DNAm alterations associated with disease phenotypes and age typically also exhibit such spatially correlated patterns, albeit much weaker 16 . Thus, calling DMRs removes some of the spatial redundancy, helping to reduce the dimensionality of the data. Second, calling differential methy lation at the regional level may offer increased robustness, especially in the context of limited-coverage WGBS data 82, 83 . Third, although still controversial, DNAm alterations that extend to the regional level are thought to be more functionally important than alterations that affect only isolated sites 84, 85 . Statistical algorithms for calling DMRs include bumphunter 86, 87 , an algorithm originally designed for high-resolution DNAm data (for example, WGBS or CHARM 88 ) but that has also been successfully adapted for Illumina Infinium BeadChips and that can allow detection of small (~1-5 kb) DMRs, as well as larger (~100 kb−2 Mb) DMRs, termed differentially methylated blocks (DMBs) [89] [90] [91] [92] [93] [94] . A more recent algorithm tailored for WGBS data, and which exploits the spatial correlation structure of DNAm, identifies regions of covariation in methylation (COMETs) 82, 83 , which can then be used as regional features for differential methylation analysis. Using COMETs to call differential methylation can result in improvements in sensitivity of greater than 40-50% compared with DMC calling, even in WGBS data with 30× coverage 82, 83 . Spatial correlation of methylation across different tissues and cell types has also been recently used to define 'methylation haplotype blocks' , which facilitates the identification of the tissue of origin of ctDNA in serum 16 . More recently, adopted methods for identifying DMRs are DMRcate 95 and Comb-p 96 . It is noteworthy that each DMR method differs in the assumptions made and statistical approach taken and that different methods therefore very rarely identify precisely the same DMRs.
Differentially variable cytosines and regions.
An entirely different feature selection paradigm is based on features that exhibit differential variance in methylation between two phenotypes, so-called differentially variable cytosines (DVCs). This approach computes the variance across samples belonging to the same phenotype and then compares this variance between two or more pheno types using a statistical test for differential variance 97 
. It is important to appreciate that DVCs may not be DMCs (and vice versa) and that there are also different types of DVCs (FIG. 2b) .
The importance of differential variance has been most clearly demonstrated in the context of early carcino genesis 68, 98 , where differential variance between normal cells from healthy individuals and normal cells at risk of neoplastic transformation is critical to the identification of DNAm alterations that define field defects in breast 55 and cervical cancer 68 (FIG. 2c) . These DNAm alterations are characterized by relatively large changes in DNAm (typically 20-30% or higher), defining outliers, that occur predominantly, or exclusively, in the samples at risk of neoplastic transformation (FIG. 2c) . As might be expected from DNAm alterations in cells that have not yet undergone neoplastic transformation, these outlier events are relatively infrequent and exhibit a stochastic pattern 55 . However, in cells that have undergone neoplastic transformation or turned invasive, the pattern of DNAm variation becomes more homogeneous and deterministic, in the sense that effectively all (or most) cancer samples exhibit a difference in DNAm (FIG. 2c) . By combining differential-variance-based feature selection with an adaptive index classification algorithm 99 in an approach called epigenetic variable outliers for riskprediction analysis (EVORA) 68 , such DVCs have been demonstrated to allow prediction of the prospective risk of cervical cancer 55 . Given the growing importance of differential variance, a number of other algorithms [100] [101] [102] have been proposed that offer an improved control of the type 1 error rate over the test implemented in EVORA. However, with a stricter control of the type 1 error rate, these other differential variance algorithms may also lack the sensitivity to detect DNAm alterations in precursor cancer lesions 103 . Thus, their application appears limited to other phenotypes (for example, neoplasia or invasive cancer).
An altogether different phenotype for which differential variance has recently been demonstrated to lead to novel insight is age 77 . Specifically, the Breusch-Pagan test for heteroscedasticity was used to identify CpGs whose DNAm variability increases with age, identifying sites that are very different to those making up age-predictive epigenetic clocks 8, 104 and that appear to be more relevant for understanding ageing mechanisms 77 .
As with differential methylation, differential variance may also be defined at the regional level. First, it has been possible to demonstrate that there are genomic regions of increased DNAm variability, so-called variably methylated regions (VMRs) 105 , also termed regions of high methylation disorder or entropy 106 . Regions that constitute VMRs in one phenotype (for example, cancer) but not in another (for example, normal tissue) are differentially variable regions (DVRs) 105 . DVR detection is possible using dedicated functions in software packages such as minfi 87 or DMRcate 95 , although the implemented differential variance tests are aimed only at controlling the type 1 error rate and may thus be underpowered for detecting epigenetic field defects in cancer studies 55 .
Interpreting DNA methylation changes. Beyond celltype composition 107 , observed DNAm alterations could be associated with deregulation of specific genes or signalling pathways in individual cell types 34, 108 . Thus, there is a strong rationale for testing the enrichment of identified features for specific gene ontology (GO) terms and signalling pathways. As multiple DMCs or DVCs may map to the same gene, it is critical to adjust for differential representation 109 to avoid spurious overrepresentation in certain pathways by virtue of a higher probe or CpG density in those genes involved. This adjustment can be done with the gometh/gseameth algorithm 110 . An alternative approach is to assign a DNAm value to a given gene, such as by focusing on the average DNAm within a certain distance of the transcription start site (TSS) 111 , and to then identify differentially methylated genes, which can be subsequently fed into popular gene set enrichment analysis (GSEA) methods 112, 113 . With a DNAm value assigned to each gene, one may also perform differential methylation analysis at the level of signalling pathways or search for differentially methylated gene modules (called 'EpiMods') within protein-protein interaction (PPI) networks 111 . For instance, such an approach demonstrated that the WNT signalling pathway, a key developmental pathway, is a hot spot of age-associated DNAm deregulation 111 .
Integration of DNAm with other types of omic data There are many factors that limit the interpretability of the DNAm data generated in a typical EWAS 114, 115 . Besides cell-type heterogeneity, genetic variation and reverse causation (that is, alterations to measured DNAm levels caused by the phenotype itself) can also cause confounding 18, 116 . As a predictor of gene expression, DNAm is also limited and outperformed by chromatin state information encoded by histone modification marks 117, 118 . Thus, enhancing interpretability requires integration with other types of omic data, including genotype or gene expression matched to the same samples for which DNAm is available.
Integration of DNAm with genotype. Total heritability of DNAm has been estimated at 20% 76, 119 , with common SNPs accounting for approximately 37% of this heritability 76 . In line with this, many studies have demonstrated that mQTLs are widespread 76, 120, 121 , accounting 
Statistical tests for DV
Bartlett's test. This test assumes normality for each of two underlying distributions being compared and is therefore sensitive to outliers. Although it suffers from a high type 1 error rate, its sensitivity to outliers (that is, deviations from normality) makes it an attractive choice because in precursor cancer lesions, DNAm outliers have been shown to be biologically relevant. This test is used in epigenetic variable outliers for risk-prediction analysis (EVORA) and iEVORA and was instrumental to identifying DNAm field defects in cervical and breast cancer (TABLE 1) .
The Levene and Brown-Forsythe tests. Levene's test compares the absolute spread of values from the mean in each group, using a one-way ANOVA F-test, whereas the Brown-Forsythe test uses the median instead of the mean, rendering it more robust. Both tests are less sensitive to departures from normality than Bartlett's test. Levene's test is implemented in the DiffVar package (TABLE 1) .
Breusch-Pagan test. This is a test for heteroscedasticity or differential variability in a response variable (here, DNAm) as a function of an independent variable with continuous values (for example, age). It works by correlating the independent variable with the residuals of a linear regression of the response variable against the independent variable. This test has been used to identify CpGs exhibiting age-associated increases in DNAm variance (see the main text).
EVORA
EVORA is a statistical framework that uses differential variability in DNAm to identify CpGs that exhibit outlier DNAm values in normal cells that are at risk of neoplastic transformation compared to normal cells that are not at risk. For a given risk-marker CpG, this method assumes that DNAm outliers may exhibit stochasticity -that is, they define infrequent events across independent samples. Feature selection using DV is combined with an adaptive index classification algorithm (effectively, a counting scheme for the number of outliers in a sample) to construct a risk score.
Differentially variable regions
(DVRs). Contiguous genomic regions containing a statistically significant number of differentially variable cytosines (DVCs). This is different from a variably methylated region (VMR) in that a DVR is derived by comparing a fairly large number of cases and controls.
Gene set enrichment analysis (GSEA). A widely used statistical procedure to assess whether a derived gene list of interest is enriched for specific biological terms, usually including gene ontologies, signalling pathways, specific transcriptomic signatures or targets of gene regulators.
System epigenomics
An emerging field whereby cellular phenotypes in normal development and disease are modelled as complex systems, using tools from complexity science (for example, dynamical system theory or statistical physics) to understand them.
for almost 40% of assayed CpG sites and explaining approximately 20% of the inter-individual variation in DNAm, with environmental effects accounting for the remaining 80% 76 . Thus, adjusting for DNAm variation induced by genetic variation is a common procedure in EWAS, which can be achieved using PCA on the matched genotype data 76, 77, 122 or directly from DNAm data if no matched genotype information is available 123 . Beyond being a source of confounding, genetically driven DNAm variation provides a useful resource for interrogating the functional role of DNAm variation in disease-associated loci. For example, functional inferences can be made by ascertaining whether disease-associated genetic variants from genome-wide association studies (GWAS) are also mQTLs (and may thus be influencing disease risk partly via epigenetic pathways) or by using genotype as a causal anchor to strengthen causal inference regarding the role of DNAm in mediating pathways to disease [124] [125] [126] 
FIG. 3A). As a concrete example, genetic variants associated with blood lipid levels were used to demonstrate a causal effect of lipid levels on DNAm in blood, whereas mQTLs associated with lipid-level DMCs in blood excluded an effect in the reverse direction 116 . Such inference can thus help to establish causal directionality in an EWAS of a disease risk factor, determining whether DNAm may mediate that risk.
Integration of DNAm with gene expression.
The relation ship between DNAm and gene expression is complex. From a modelling perspective, the first challenge is that it is not only the DNAm profile of the gene itself but also the DNAm levels at distal regulatory elements, notably enhancers, that dictate the expression level of a gene. In the context of cancer, distal regulation by DNAm patterns at enhancers appears to account for more of the intertumour expression variation than corresponding DNAm changes at promoters 127 . However, expression variation should be assessed primarily against the normal tissue reference (which is often not done), and adjustment for cell-type heterogeneity is imperative, as enhancers are among the most cell-type-specific regions 108, 128 . Also problematic is that most enhancers loop over their nearest genes to target genes much further away, causing uncertainty as to which genes an enhancer may regulate. Although improved statistical methods for linking enhancers to their putative gene targets are emerging 129 , these still need further improvement. Focusing on the gene itself, a third challenge is to ascertain which part of a gene's DNAm profile is most predictive of its transcript level, as this may also depend on biological context and is still a matter of debate, with some studies suggesting gene-body methylation levels as being more predictive than the more classical TSS region [130] [131] [132] . However, a meta-analysis of human genome-wide methylation, expression and chromatin data has demonstrated that the relationship between gene-body methylation and gene expression is non-monotonic, with the genes expressed at the lowest and highest levels exhibiting the highest levels of genebody methylation 133 . This meta-analysis is consistent with other studies demonstrating that it is the TSS, first exon and 3ʹ end that exhibit the strongest monotonic associations 85, 134, 135 . At the TSS and first exon, the correlation is usually negative, characterized by a highly nonlinear 'L'-shape function: that is, methylated promoters are generally associated with gene silencing, whereas unmethylated promoters associate with both transcribed and untranscribed states 136 . Focusing on a specific predictive region such as the first exon or TSS allows assignment of a DNAm value to each gene, such as by averaging DNAm values for CpGs in this region. The monotonic relation (be it linear or nonlinear) between DNAm and transcription in these regions further facilitates subsequent integration with gene expression or with other gene-level omic data (for example, copy-number variants). Importantly, the procedure of assigning a DNAm value to a gene is a necessary preliminary step for integrative clustering analyses using tools such as iCluster+, which perform joint clustering of samples over a common set of features (usually genes) defined for different data types [137] [138] [139] .
Other attempts at integration of DNAm and gene expression do not assign a unique DNAm value to a gene; instead, they use information about the spatial shape of the DNAm profile over a gene (and beyond) as a predictor of gene expression 84, 85 . Such an approach requires DNAm data at high resolution (for example, WGBS) to then perform unsupervised clustering of gene-based spatial DNAm profiles, typically centred on a 10-30 kb window around the TSS of genes, and subsequently using special distance metrics to quantify the similarity of spatial DNAm profiles 84 . This novel approach identified 4-5 spatially distinct DNAm shapes, each correlating with underexpression or overexpression in cis 84 , further confirming that DNAm patterns that extend well beyond the 5ʹ and 3ʹ ends of a gene are equally informative of gene expression 15, 108 . More recently, a supervised version of this spatial clustering method, which uses a random-forest classifier called ME-Class, has been shown to improve the prediction of gene expression, highlighting the importance of the TSS and 3ʹ end as the most predictive gene regions 85 .
System-level integration of DNAm.
A powerful system-level integrative approach is to exploit the wellknown association of DNAm at regulatory elements with TF binding [140] [141] [142] [143] [144] [145] to infer patterns of regulatory activity in development and disease. Although DNAm at regulatory sites has traditionally been viewed as dictating TF binding affinity, the converse (that is, DNAm levels at regulatory sites being a reflection of binding activity) is also frequently observed 115, 142 . Furthermore, whereas for most classes of TFs, in which DNAm inhibits or is inversely correlated with binding, there are other classes of TFs (for example, those belonging to the homeodomain, POU and NFAT families) that prefer binding to methylated sequences 143 . Thus, although the relationship between DNAm and TF binding is undoubtedly complex, two recent key observations have helped to spur a number of novel system epi genomics methods for inferring TF binding activity. One key observation is that tissuespecific TFs can be identified as those with enrichment Pleiotropy A phenomenon that occurs when a genetic variant is associated with multiple traits. Vertical pleiotropy occurs where the traits are all on the same pathway (and is generally less of a problem), whereas horizontal pleiotropy exists where a genetic variant is associated with multiple traits via separate pathways.
Expression quantitative trait loci
(eQTLs). Genes whose expression levels are correlated with single-nucleotide polymorphisms (SNPs). If the SNP occurs near (definitions vary, but it could range from 10 kb to a 1 Mb window centred on the transcription start site) the gene, it is called a cis-eQTL; otherwise, it is a trans-eQTL.
in unmethylated or relatively hypomethylated binding sites 108 . Although this was demonstrated by integrating WGBS and Encyclopedia of DNA Elements (ENCODE) ChIP-seq data across multiple different cell types 108 , other studies have shown that similar inferences are possible with lower resolution Infinium methylation bead arrays 91 .
A second key observation is that integration of transmQTLs with cis expression quantitative trait loci (cis-eQTLs) can reveal coordinated DNAm alterations at binding sites of a TF whose expression is altered by the SNP, thus providing an important novel paradigm for elucidating the downstream effects of non-coding GWAS SNPs 122 (FIG. 3B) .
Box 3 | Statistical approaches for establishing mediation by DNA methylation
DNA methylation (DNAm) is a molecular phenotype that is influenced by endogenous and exogenous factors as well as disease processes themselves, and this presents challenges in understanding the correlations between measures of interest. A variety of statistical methods have been applied to dissect causal relationships and to construct causal pathways involving molecular intermediates including DNAm. These methods have been applied to differentially methylated cytosines (DMCs) only and have yet to be extended to consider the mediating role of differentially methylated regions (DMRs).
Exposure-outcome mediation
The most commonly applied approach in epidemiology is a regression-based method originally proposed by Baron and Kenny 199 that aims to distinguish the degree of mediation of an exposure (E) on an outcome (Y) by an intermediate (M). The Sobel test is applied to ascertain whether the effect of E on Y is statistically significant once adjusted for M.
Advantages
• It is simple to administer.
• The proportion of mediation can be quantified.
Disadvantages
• It requires strong assumptions that are often violated when applying it to molecular mediators. These assumptions include (i) that Y and M are continuous and (ii) that there is no measurement error in the mediator.
• This method should be applied only in the context of complete (not partial) mediation, which is usually not the case when considering DNAm.
• Other, more flexible methods have been applied to DNAm data, including linear equations, structural equation models, marginal structural models and G-computation; however, these approaches all require assumptions of no measurement error and no unmeasured confounding, which are violated in analyses involving DNAm.
Causal inference test (CIT)
This popular approach for exploring causal links in DNAm analyses uses genetic variation as a causal anchor. It is analogous to the Baron and Kenny approach in its use of a series of regression analyses to establish mediated effects but uses genotype (G) in place of the exposure (E). This approach has been used to infer the causal effect of methylation quantitative trait loci (mQTLs) on a particular outcome 30 .
Advantages
• It avoids confounding and reverse causation in the mediator-outcome relationship by using genotype as a causal anchor.
• It is simple to apply.
Disadvantages
• It relies on a P-value to determine the causal effect and does not estimate the magnitude of the mediated effect.
• It is vulnerable to measurement error in the mediator or outcome.
• It cannot differentiate between a mediated effect and a situation in which the genetic variant directly influences the outcome via an alternative biological pathway (pleiotropy).
Mendelian randomization
This form of instrumental variable (IV) analysis makes use of genetic variants that are robustly associated with the exposure (E) or mediator (M) of interest. It can also be applied in the reciprocal direction to evaluate the direction of cause from a postulated outcome (Y) on the apparent exposure or mediator. The assumptions of Mendelian randomization (MR) are detailed at length elsewhere 200 . Its application in the context of DNAm is becoming more widespread 116, [201] [202] [203] , and an automated platform for MR analysis is freely available (http://www.mrbase.org/) to facilitate this (see TABLE 1 ).
Advantages
• It provides an estimate of the magnitude of the mediated effect.
• It overcomes the issue of measurement error in the mediator because genotype is usually measured accurately.
• It is readily applicable through online tools.
Disadvantages
• It is reliant on the identification of cis-mQTLs to tag the differentially methylated site of interest.
• It has low power, which necessitates the use of large sample sizes.
• The potential pleiotropy of genetic variants, although strategies can be adopted to counter this limitation 204, 205 .
This inverse correlation between DNAm and regulatory-element activity can be exploited by computational tools to infer disrupted regulatory networks associated with disease risk factors 51, 91, 122, 146 and disease itself 127, 147, 148 . For instance, the enhancer linking by methy lation/expression relationships (ELMER) algorithm 147 (TABLE 1) begins by identifying enhancers (annotated by ENCODE and the Roadmap Epigenomics Mapping Consortium 15, 149 ) whose DNAm levels are altered in cancer. It then uses the matched mRNA expression of putative gene targets to construct cancer-specific enhancer-gene networks. ELMER subsequently uses TF-binding motif enrichment analysis for correlated enhancers and mRNA expression of enriched TFs to identify cancer-specific activated TFs. Other similar approaches, such as tracing enhancer networks using epigenetic traits (TENET) 150 and RegNetDriver 151 , have recently been proposed (TABLE 1) . RegNetDriver constructs tissue-specific regulatory networks by integrating cell-type-specific open-chromatin data with regu latory elements from ENCODE and RMEC, allowing active regulatory elements in a tissue to be identified. Mapping disease-associated molecular alterations in that tissue onto the corresponding tissue-specific network can reveal which TFs are deregulated in disease 151 . All these tools can lead to important novel hypotheses (for example, ELMER identified RUNX1 as a key TF determining clinical outcome in kidney cancer), as well as novel insights (for example, RegNetDriver revealed that most of the functional alterations of TFs in prostate cancer were associated with DNAm changes but that TF hubs were preferentially altered at the copy-number level). However, obvious limitations remain: the sets of enhancer regions used are usually not cell-type-specific or were generated in unrepresentative cell-line models, while linking genes to enhancers and vice versa is challenging as most enhancers skip their nearest promoter to link to genes that are much further away (contact distances can range from 40 kb to 3 Mb with a median distance of ~180 kb 152, 153 ). Although tools like ELMER and TENET use correlations between enhancer DNAm and mRNA target expression to hone in on the more likely targets, these correlations are themselves subject to potential confounders such as cell-type heterogeneity.
Another valuable system-level integrative strategy, exemplified by the functional epigenetic modules (FEM) algorithm (TABLE 1) , has been to integrate DNAm and gene expression data in the context of a gene function network, for instance a PPI network, to identify hot spots (gene modules) where there is significant epigenetic deregulation in relation to some phenotype of interest 134, 154 (FIG . 3C) . There are two main reasons why integration of DNAm with a PPI network is meaningful. First, PPI networks encode information about which proteins interact together and which are therefore more likely to be coexpressed as part of a common biological process or signalling pathway. This co-expression is likely to be under epigenetic control and therefore potentially measurable from DNAm patterns at the corresponding genes 111 . Indeed, like gene expression, DNAm also exhibits modularity in the context of a PPI network, whereby promoter DNAm levels of genes whose proteins interact are on average more highly correlated than those of non-interacting proteins 111 (FIG. 3C) . Second, using a functional network from the outset and searching for subnetworks where there is simultaneous differential methylation and differential expression can help to identify biological pathways or processes that are epi genetically deregulated, which in turn may lead to novel insight. This is not dissimilar to performing a direct form of GSEA but using a network instead of an external database of biological terms. Similar supervised functional network algorithms have been extensively applied in the gene expression context, leading to important novel insights [155] [156] [157] . As an example of the insights gained using FEM, it successfully identified two separate gene modules with the main targets of epigenetic silencing mapping to a target (HAND2) and co-activator (TGFB1I1) of the progesterone receptor, a key tumour suppressor pathway for which inactivation is thought to contribute causally to the development of endometrial cancer 134, 154 . More recently, other algorithms that extend or modify FEM have been proposed 158, 159 (TABLE 1) . The algorithm 'significance-based modules integrating the transcriptome and epi genome' (SMITE) 160 can identify DNAm-mediated altered cellular states (for example, gene modules) without the need for direct integration with a PPI network, thus allowing a larger gene-space to be explored. In summary, although these methods can substantially improve the interpretation of DNAm changes in EWAS, they are nevertheless limited by the quality of the modelling between methylation and gene expression.
Another set of integrative algorithms are tailored for integrating DNAm data that are generated in conjunction with other data types for the same samples: for instance, this may include mutations, copy-number variants (CNVs), mRNA, microRNAs (mi RNAs) and protein expression 161 . Analysing individual data types separately and subsequently correlating resulting clusters has been a popular strategy 162 ; however, performing simultaneous inference using all data types together offers, in principle, a much more powerful and unbiased framework in which to identify system-level associations and extract novel biological insight. For instance, simultaneous inference may help to identify genes that are deregulated epigenetically or through CNVs in a mutually exclusive fashion 151, 163 . Although many statistical algorithms for multi-omic integrative ana lyses exist, their application to multi-omic data remains challenging, owing to the high-dimensional nature of the data but also because the effect of confounders on the inference is poorly understood. So far, a joint NMF algorithm was applied to the matched DNAm, mRNA and miRNA expression data sets for ovarian cancer from The Cancer Genome Atlas (TCGA), revealing novel perturbed pathways 164 . An integrative DNAm and mRNA analysis of oestrogen receptor (ER) + breast cancer used a joint latent variable algorithm, called iCluster/iCluster+ 137, 139, 165 , demonstrating that ER + breast cancer transcriptomic subtypes differ epi genetically mainly only in terms of the level of DNAm deregulation 138 . Other algorithms and techniques for joint multi-omic matrix factorization analyses are available,
TF hubs
In the context of a regulatory network where edges represent regulatory interactions between transcription factors (TFs) and target genes, those TFs with the largest number of interactions. trans-mQTLs trans-mQTLs yet they remain largely unexplored in a DNAm context. For instance, joint and individual variation explained (JIVE) (TABLE 1) is a powerful multi-dimensional matrix factorization algorithm that can identify sources of data variation that are common to multiple data types, as well as those that are unique to each data type 166, 167 . If multi-omic data are matched across all dimensions (for example, the same genes and samples measured for two different tissues or data types), they can be packed into a multi-dimensional array known as a tensor, for which non-Bayesian (parallel factor analysis (PARAFAC) 168 ) and Bayesian (sparse decomposition analysis (SDA) 169 ) tensor decomposition algorithms are available (TABLE 1) . By approximating the data tensor as a sum of products of simple latent component vectors, one for each data type, these models are readily interpretable, with the Bayesian version less prone to overfitting. A recent study applied SDA to a third-order tensor of expression values defined over 20,000 genes, 845 individuals and 3 tissue types (skin, adipose and lymphoblasts), subsequently correlating the latent components to SNPs and revealing trans-eQTL gene networks that were either common or unique to different tissue types, thus helping to delineate tissue-specific functional effects of GWAS SNPs 169 . Thus, tensorial methods should also be particularly suitable for elucidating tissue-specific and tissue-independent mQTLs in EWAS profiling multiple tissue types.
Conclusions and future directions
Recent studies underline the importance of DNAm as a focal point for elucidating and understanding diverse phenomena, including ageing phenotypes 8, 77, [170] [171] [172] , functional effects of GWAS variants 30,122 , the causal pathways between environmental factors and disease risk 18, 51, 154, 173, 174 , cell-type heterogeneity and stochas ticity 63, 68, 174, 175 , cancer evolution and metastasis 66, 67, 69, 176, 177 and 3D chromatin architecture 106, 178 . Furthermore, they highlight potential downstream applications, including cancer risk prediction 68, 179, 180 , prediction of frailty and all-cause mortality [181] [182] [183] and non-invasive detection of cancer and tissue of origin from ctDNA in blood plasma 16, 40, 184 . For many of these efforts, cell-type heterogeneity and deconvolution will continue to pose challenges. Indeed, most of the algorithms for system-level integration that compute correlations between features do not adjust for cell-type heterogeneity, yet this adjustment is paramount for correct interpretability. Another outstanding challenge is that current algorithms do not allow for the identification of the specific cell type (or types) carrying the DMCs, thus requiring laborious follow-up experimental validation in purified samples. The potential limitation of cell-cell interactions for the accuracy of reference profiles used in reference-based inference also needs to be assessed. Hybrid approaches that generate reference DNAm (or RNA-seq) profiles for different types of single cells in a small number of individuals could be a fruitful strategy for constructing improved reference profiles that are tailored to the tissue of interest 185 . Ultimately, the level of resolution required by cell-type deconvolution strategies also needs to be determined, as epigenetic and DNAm hetero geneity exists right down to the single-cell level 186 . Thus, quantification of functional epigenetic heterogeneity will be a key problem for the future. Related to this, it is also unclear whether DNAm or mRNA expression is better suited for cell-type deconvolution 26, 34, 37 and whether joint analysis of data types could further improve inference. The generation of gold-standard data sets, artificial and real, is challenging yet absolutely necessary to ensure objective comparisons of existing and upcoming statistical algorithms 48 . In particular, a large comparative and comprehensive analysis of cell-type de convolution algorithms, including novel semi-reference-free methods, which are particularly amenable for Bayesian treatment, is urgently needed.
Feature selection and inference of causality in EWAS also remain a considerable challenge, even when Ab | To strengthen causal inference from exposure to outcome and from exposure to mediator, a genetic variant (G1) or combination of multiple variants that robustly correlate with the exposure can be used. Solid lines represent the established association of the instrumental variable (single-nucleotide polymorphism (SNP)) with the factor for which it is acting as a proxy, and dashed lines represent the relationships being tested in the Mendelian randomization (MR) framework. The association of G1 with the outcome (and mediator) provides evidence of a causal impact of the exposure on these factors. Ac | When considering the causal pathway from the mediator (DNA methylation (DNAm)) to the outcome, a second genetic variant (G2) or combination of multiple variants can be used. G2 is a cis methylation quantitative trait locus (cis-mQTL) that robustly correlates with the DNAm site of interest. Details of the statistical methods to implement this MR approach are further described in BOX 3. G1 and G2 analyses can, if desired, be conducted in entirely different sample sets with causal inference remaining valid. Ad-f | An application of this conceptual framework is shown in which the exposure-outcome setting is smoking and lung cancer and the proposed mediator is DNAm at the AHRR gene locus 173 . SNPs at the CHRNA locus are an established proxy for smoking heaviness and have been used in an MR framework 206 . Their application here can corroborate established evidence for the causal role of smoking in lung cancer as well as interrogate the causal role for methylation as a mediating mechanism. B | Integration of DNAm data with matched SNPs and mRNA expression can be used to elucidate the role of genome-wide association study (GWAS) SNPs. For instance, a genetic variant defining a cis expression QTL (cis-eQTL) for a transcription factor (TF) can be found to be associated with a large number of trans-mQTLs. For cis-eQTLs associated with increased TF activity, these trans-mQTLs exhibit a skew towards hypomethylation (loss of methylation is indicated by the transition C m (methylated cytosine) to C (cytosine)) and are enriched for binding sites of this TF and for cis expression quantitative trait methylation loci (cis-eQTMs) defined by the corresponding TF gene targets. An example of a SNP associated with ulcerative colitis illustrates how relevant disrupted pathways can be identified 122 . C | Like mRNA expression, promoter DNAm exhibits modularity, that is, stronger correlations between genes that interact in a gene-functional network (for example, a protein-protein interaction (PPI) network). This modularity and the association between promoter DNAm and mRNA expression can be exploited to identify gene modules that are significantly deregulated at both transcriptomic and epigenetic levels. The Functional Epigenetic Modules (FEM) algorithm (TABLE 1) can be used to identify such hotspots of deregulation. A successful application of FEM to endometrial cancer uncovered the gene HAND2, a target of the progesterone receptor, which is hypermethylated and silenced in pre-neoplastic lesions and in cancer and which has been shown to drive endometrial carcinogenesis 134, 154 . Another gene module is centred around TGFB1I1 (also known as HIC5), a known co-activator of the progesterone receptor. Part C is adapted with permission from REF. 207 , Springer. 
Tensor
A multi-dimensional array with the number of dimensions often called the 'order' or 'rank' of the tensor and for which linear decomposition algorithms are available, analogous to linear matrix factorization algorithms for data matrices. Scalars, vectors and matrices are tensors of order 0, 1 and 2, respectively. adjustment for cell-type heterogeneity is possible, as features may still be susceptible to reverse causation or confounding by other unknown factors. Longitudinal prospective studies can avoid some reverse causation effects, and using genotype as a causal anchor via Mendelian randomization can further help to exclude the effects of confounders, but all this does not currently provide a panacea to the problem. Causal inference methods often rely on model assumptions (for example, linearity) that may not hold and that may lead to residual confounding and to wrong or conflicting con clusions. Measurement errors, such as in epidemiological variables, further exacerbate this problem. Thus, as recently proposed 115 , causal inference methods may need to incorporate prior biological information from the outset in order to strengthen inference: for instance, guided by recent studies demonstrating that trans-mQTLs at TF binding sites could help to delineate the effects of non-coding GWAS SNPs 122 , it will be of great interest to extend causal-inference methodology to such multi-locus scenarios. Alternatively, breakthrough experimental techniques that allow single-locus and multi-locus epigenome editing 187 will shed new light on epigenetic function and causality, yet these will also require the development of novel statistical procedures to fully interpret the effects of epigenetic perturbations. Another emerging challenge for feature selection is the presence of stochastic epi genetic perturbations, exemplified by DNAm outliers in normal tissue that predate disease onset and that may be indicators of disease risk (for example, normal tissue at risk of cancer development) 55 . A particular challenge is distinguishing DNAm outliers that mark shifts in the epiallele composition of a tissue (contributing to epigenetic mosaicism) from DNAm outliers driven by technical or other confounders. More generally, analysing DNAm in conjunction with other epigenetic and functional data promises to improve our understanding of 'system epigenomics' . However, this will require sophisticated statistical modelling, which could benefit from harnessing innovative approaches used in other fields, such as engineering, artificial intelligence and physics. Although the value of advanced machine-learning methods (for example, deep neural networks) is undeniable 15, 129, 188, 189 , extracting novel biological insight from them is often limited. Thus, we envisage that phenomenological models inspired or built on physical models [190] [191] [192] [193] could capture the right level of complexity to extract and harness useful biological insight. Along these lines, integrative analysis of multi-omic data, potentially at the single-cell level and within the framework of statistical mechanics models 186, 191, [194] [195] [196] [197] [198] , may allow construction of epigenetic landscapes as envisaged by Waddington 106, 193 , which in turn may help to elucidate systems-biological principles underlying diverse phenomena such as tissue homeostasis and cancer.
The rapid growth and availability of statistical tools to integrate, analyse and make inferences about DNAm data are encouraging. Such developments continue to address the challenges faced by the field, and fundamental to these developments is an understanding of both the statistical characteristics of the data being used as well as the biological phenomena they represent. 
Mendelian randomization
A technique to estimate the effect of an exposure on an outcome using genetic variants and instrumental variables for the exposure. This approach can also be applied to assessing mediation.
